Kaloban

Pelargonium sidoides root extract, the active ingredient in Kaloban, is a herbal medicine presented as a liquid oral preparation for oral use. It is traditionally employed to support relief of symptoms associated with acute respiratory infections in adults and children.

GNH USA supplies Kaloban as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kaloban is used as a supportive therapy for respiratory conditions that involve inflammation and mucus production.

Acute bronchitis: may help reduce cough frequency and improve symptom resolution. Sinusitis: may support clearance of nasal discharge and reduce congestion. Upper respiratory tract infection: may alleviate general cold symptoms such as sore throat and malaise.

Kaloban, like other herbal extracts, may be associated with adverse reactions, although most users tolerate it well.

Common Side Effects: - Gastrointestinal discomfort: mild nausea or stomach upset. - Taste disturbance: bitter or unpleasant taste. - Allergic skin reaction: mild rash or itching.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema. - Hepatic dysfunction: elevated liver enzymes. - Blood dyscrasia: rare cases of neutropenia.

When considering Kaloban, several precautions should be observed to ensure safe use.

Pregnancy: safety not established; avoid unless prescribed. Breastfeeding: insufficient data; consult a healthcare professional. Pediatric use: limited evidence; use only under medical supervision. Drug interactions: review concomitant medications for potential interactions. Underlying liver disease: monitor liver function. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Kaloban may interact with certain medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Immunosuppressants (e.g., cyclosporine): possible reduced efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensives: potential additive blood pressure lowering. - Antidiabetic agents: may enhance glucose‑lowering effect. - CYP450 substrates: possible modulation of metabolism.